Yahoo
Shanghai - Delayed Quote CNY

Shanghai MicroPort Endovascular MedTech Co., Ltd. (688016.SS)

86.34 +0.47 (+0.55%)
At close: 3:00:00 PM GMT+8
Chart Range Bar
Loading chart for 688016.SS
  • Previous Close 85.87
  • Open 86.46
  • Bid 86.34 x --
  • Ask 86.35 x --
  • Day's Range 84.80 - 87.19
  • 52 Week Range 81.98 - 116.00
  • Volume 1,579,732
  • Avg. Volume 1,300,147
  • Market Cap (intraday) 10.642B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 18.10
  • EPS (TTM) 4.77
  • Earnings Date --
  • Forward Dividend & Yield 2.60 (3.03%)
  • Ex-Dividend Date Oct 20, 2026
  • 1y Target Est 127.25

Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, manufacturing, sale, and services of aortic, peripheral vascular, and tumor intervention devices in China and internationally. The company offers Fontus, a branched stent graft system in surgical operation; CRONUS, a stent graft system in surgical operation; Hector, a multi-branch thoracic stent graft system; Cratos and Castor, a branched aortic stent graft system; Talos, a thoracic stent graft system; and Hercules, a thoracic stent graft system with low profile delivery system. It also provides Minos, an abdominal aortic stent graft and delivery System; Aorfix, an endovascular device designed for treating abdominal aortic aneurysms; Altura, a device designed for the endovascular repair of abdominal aortic aneurysms; Aegis, a bifurcated aortic stent graft system; and L-REBOA, an aortic occlusion balloon catheter. In addition, the company offers Reewarm PTX, a drug coated balloon PTA catheter; ReeAmber, a PTA balloon dilatation catheter; Reewarm, a PTA balloon dilatation catheter; Ryflumen, a peripheral high-pressure balloon dilatation catheter; and CROWNUS, a peripheral stent system; HawkMaster, a detachable fibered embolization coils; HawkNest, a fibered embolization coils; Veryan BM3D, which is designed for the treatment of symptomatic de novo lesions in the native superficial femoral artery; Vflower, a venous stent system; SeaDragon, a PTA balloon dilatation catheter; Vewatch, a vena cava filter; Vepack, a snare retrieval kit; VeinPro, an endovenous radiofrequency closure system; Reflow-speX, a support catheter; and DEMANTOID, a peripheral vascular guide wire. Further, it provides Tipspear, a transjugular liver access set. Shanghai MicroPort Endovascular MedTech Co., Ltd. was incorporated in 2012 and is based in Shanghai, the People's Republic of China.

www.endovastec.com

822

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

688016.SS
3.37%
SSE Composite Index (000001.SS)
8.34%

1-Year Return

688016.SS
13.07%
SSE Composite Index (000001.SS)
8.01%

3-Year Return

688016.SS
27.29%
SSE Composite Index (000001.SS)
20.89%

5-Year Return

688016.SS
38.57%
SSE Composite Index (000001.SS)
3.78%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY24
Revenue 236.91M
Earnings -55.48M
Profit Margin -23.42%

Q1

FY24

Q2

FY24

Q3

FY24

Q4

FY24

0
100M
200M
300M
400M
-20.0%
0.0%
20.0%
40.0%
60.0%
80.0%

Analyst Insights

View More

Analyst Price Targets

94.00
127.25 Average
86.34 Current
150.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    40.06%

  • Return on Assets (ttm)

    7.57%

  • Return on Equity (ttm)

    13.85%

  • Revenue (ttm)

    1.45B

  • Net Income Avi to Common (ttm)

    582.84M

  • Diluted EPS (ttm)

    4.77

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.08B

  • Total Debt/Equity (mrq)

    0.33%

  • Levered Free Cash Flow (ttm)

    89.33M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: